[ACOR] Acorda Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 1.15 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 18.15 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart ACOR

Refresh chart

Strongest Trends Summary For ACOR

ACOR is in the long-term down -61% below S&P in 14 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company?s products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain. It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trail for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the trea

Fundamental Ratios
Shares Outstanding46.07 M EPS-1.16 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 2.8% Sales Growth - Q/Q-15.29% P/E-14.87
P/E To EPS Growth P/S2.74 P/BV2.1 Price/Cash Per Share3.83
Price/Free Cash Flow16.48 ROA1.26% ROE2.53% ROI1.53%
Current Ratio3.47 Quick Ratio3.09 Long Term Debt/Equity0.96 Debt Ratio0.22
Gross Margin80.15% Operating Margin7.54% Net Profit Margin3.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.63 M Cash From Investing Activities-116.04 M Cash From Operating Activities-9.25 M Gross Profit90.84 M
Net Profit1000 K Operating Profit5.69 M Total Assets1.1 B Total Current Assets408.31 M
Total Current Liabilities460.01 M Total Debt292.68 M Total Liabilities540.27 M Total Revenue113.71 M
Technical Data
High 52 week32.6 Low 52 week13.8 Last close32.6 Last change7.24%
RSI96.12 Average true range1.73 Beta1.06 Volume622.39 K
Simple moving average 20 days27.01% Simple moving average 50 days34.29% Simple moving average 200 days35.16%
Performance Data
Performance Week23.72% Performance Month38.14% Performance Quart27.34% Performance Half57.11%
Performance Year92.9% Performance Year-to-date51.98% Volatility daily2.78% Volatility weekly6.22%
Volatility monthly12.76% Volatility yearly44.18% Relative Volume329.71% Average Volume497.09 K
New High New Low

News

2019-03-19 07:00:00 | Acorda to Present New Long-Term Data for INBRIJA™ levodopa inhalation powder at Academy of Managed Care Pharmacy Annual Meeting

2019-03-16 09:30:01 | Acorda ACOR Down 6% Since Last Earnings Report: Can It Rebound?

2019-03-15 17:45:09 | Acorda Therapeutics ACOR Gains But Lags Market: What You Should Know

2019-03-15 15:28:32 | Should You Be Concerned About Acorda Therapeutics, Inc.’s NASDAQ:ACOR ROE?

2019-03-08 07:00:00 | Acorda Therapeutics Announces Management Changes

2019-03-06 07:00:00 | Acorda to Present at Oppenheimer’s 29th Annual Healthcare Conference

2019-03-05 19:17:38 | Glancy Prongay & Murray LLP Announces Investigation on Behalf of Acorda Therapeutics, Inc. Investors ACOR

2019-03-04 00:00:00 | Detailed Research: Economic Perspectives on Huntsman, eHealth, Ionis Pharmaceuticals, Arch Capital Group, Copart, and Acorda Therapeutics — What Drives Growth in Today's Competitive Landscape

2019-02-28 16:00:00 | Acorda Therapeutics Announces Commercial Launch of INBRIJA™ levodopa inhalation powder

2019-02-26 07:00:00 | Acorda Therapeutics to Present at Cowen Annual Health Care Conference

2019-02-19 07:00:00 | Acorda Therapeutics to Present at Leerink Global Healthcare Conference

2019-02-18 17:31:12 | Edited Transcript of ACOR earnings conference call or presentation 14-Feb-19 9:30pm GMT

2019-02-15 10:29:03 | Acorda ACOR Q4 Earnings and Revenues Surpass Estimates

2019-02-15 10:02:14 | Acorda Therapeutics ACOR Q4 2018 Earnings Conference Call Transcript

2019-02-14 17:25:10 | Acorda Therapeutics ACOR Tops Q4 Earnings and Revenue Estimates

2019-02-14 16:28:31 | Acorda: 4Q Earnings Snapshot

2019-02-14 16:00:00 | Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2018

2019-02-14 07:50:18 | The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial

2019-02-08 08:03:37 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

2019-02-06 08:40:01 | Array BioPharma ARRY Soars: Stock Adds 11% in Session

2019-02-04 07:00:00 | Acorda Appoints Peter S. Carbone Senior Vice President, Quality

2019-02-01 07:55:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Rexnord, Carlisle Companies, Acorda Therapeutics, Valmont Industries, Reliance Steel & Aluminum, and Thermo Fisher Scientific — New Research Emphasizes Economic Growth

2019-02-01 07:00:00 | Acorda Fourth Quarter/Year End 2018 Update Webcast/Conference Call Scheduled for February 14, 2019

2019-01-31 09:30:02 | Is Acorda Therapeutics ACOR Stock Outpacing Its Medical Peers This Year?

2019-01-29 14:05:54 | Have Insiders Been Selling Acorda Therapeutics, Inc. NASDAQ:ACOR Shares?

2019-01-29 08:02:50 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

2019-01-24 10:46:03 | Vertex Terminates COO Ian Smith on Code of Conduct Violation

2019-01-22 09:31:02 | Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids

2019-01-22 08:39:01 | Aerpio ARPO Jumps: Stock Rises 7.8%

2019-01-17 18:30:00 | Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA™ levodopa inhalation powder

2019-01-15 08:58:01 | Nabriva Therapeutics NBRV Jumps: Stock Rises 6.7%

2019-01-15 08:01:49 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

2019-01-14 09:46:02 | ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study

2019-01-14 08:42:01 | Apellis Pharmaceuticals APLS in Focus: Stock Moves 7.1% Higher

2019-01-11 08:01:46 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

2019-01-10 10:00:03 | Acorda ACOR Plans to Launch Inbrija in Q1: What to Expect

2019-01-09 08:39:01 | Mirati Therapeutics MRTX Catches Eye: Stock Jumps 5.4%

2019-01-09 08:01:49 | See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

2019-01-07 08:46:01 | Myriad Genetics MYGN Catches Eye: Stock Jumps 6.9%

2019-01-07 08:00:00 | Acorda Provides 2018 Highlights and 2019 Guidance at J.P. Morgan Healthcare Conference

2018-12-26 09:47:02 | Company News For Dec 26, 2018

2018-12-26 09:45:51 | Acorda's Prospects Remain Dubious Despite Inbrija Approval, Says Bearish Raymond James

2018-12-26 09:34:02 | Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal

2018-12-26 07:30:00 | Biotech News Driving These Companies

2018-12-24 13:30:00 | Why Mindbody, New Gold, and Acorda Therapeutics Jumped Today

2018-12-24 13:11:17 | Biotech Stock Flies After FDA Approves Parkinson's Treatment

2018-12-24 09:41:40 | Acorda Rises 9.7 Percent After FDA Gives Nod for Parkinson's Therapy

2018-12-24 08:59:01 | Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija

2018-12-24 07:20:00 | Acorda Therapeutics' Inbrija Parkinson's disease treatment gets FDA OK

2018-12-24 07:00:00 | ADDING MULTIMEDIA Acorda Therapeutics Announces FDA Approval of INBRIJA™ levodopa inhalation powder